다발성 경화증 임상시험 현황 : 동향과 분석(2026년판)

The clinical trial landscape is evolving rapidly as pharmaceutical companies and research organizations investigate novel immunotherapies, remyelination therapies, neuroprotective agents, stem cell-based approaches, and biomarkers aimed at slowing disease progression and improving long-term patient outcomes.

Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and progressive neurodegeneration. The disease affects millions of people worldwide and remains one of the leading causes of neurological disability among young adults. Although numerous disease-modifying therapies (DMTs) have transformed disease management, unmet clinical needs remain for progressive forms of MS, remyelination, neuroprotection, and long-term disability prevention. Clinical trial landscape analysis provides comprehensive insights into ongoing and completed studies, investigational therapies, clinical development phases, sponsor activities, study designs, regulatory progress, and future commercialization opportunities.

Market Drivers

Growing Development of Disease-Modifying Therapies

Continuous innovation in disease-modifying therapies remains a major driver of MS clinical research. Developers are evaluating next-generation immunomodulators, B-cell therapies, Bruton tyrosine kinase (BTK) inhibitors, remyelination therapies, and neuroprotective agents designed to improve efficacy while reducing long-term disability progression.

Increasing Investment in Neuroimmunology Research

Pharmaceutical companies, biotechnology firms, academic institutions, and government organizations continue to increase investment in MS research. Growing understanding of immune mechanisms, genetic risk factors, and disease biology is accelerating clinical development across multiple therapeutic approaches.

Advancements in Clinical Trial Design

Modern MS clinical trials increasingly utilize adaptive study designs, digital monitoring technologies, imaging biomarkers, decentralized clinical trials, and real-world evidence to improve trial efficiency, patient recruitment, and long-term outcome assessment.

Supportive Regulatory Environment

Regulatory agencies continue to support innovation through accelerated development pathways, orphan drug incentives for applicable indications, and collaborative regulatory programs, encouraging continued investment in MS clinical research.

Market Restraints

Complex Disease Heterogeneity

Multiple sclerosis presents considerable clinical variability across relapsing-remitting, secondary progressive, and primary progressive disease forms, making patient selection and endpoint evaluation challenging during clinical development.

Long Clinical Development Timelines

MS trials typically require extended follow-up periods to evaluate relapse rates, disability progression, MRI outcomes, and long-term safety, increasing development complexity and overall research costs.

Patient Recruitment Challenges

Recruitment remains challenging due to strict eligibility criteria, prior treatment exposure, disease variability, and increasing competition among ongoing clinical studies.

Clinical Trial and Technology Insights

The global multiple sclerosis clinical trials landscape can be segmented by clinical development phase, therapeutic approach, disease subtype, sponsor type, study design, and geography.

By clinical development phase, the landscape includes preclinical research, Phase I, Phase II, Phase III, and post-marketing studies. Mid- and late-stage clinical programs account for a significant portion of ongoing development due to the expanding pipeline of disease-modifying therapies.

By therapeutic approach, clinical trials include immunomodulators, monoclonal antibodies, BTK inhibitors, stem cell therapies, remyelination therapies, neuroprotective agents, gene therapies, cell therapies, and combination treatment strategies.

By disease subtype, research focuses on relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPMS), primary progressive multiple sclerosis (PPMS), and clinically isolated syndrome (CIS).

By sponsor type, studies are conducted by pharmaceutical companies, biotechnology firms, academic medical centers, government research organizations, and international collaborative research networks.

Technological innovations including artificial intelligence-assisted trial design, advanced MRI imaging, digital biomarkers, wearable monitoring devices, electronic patient-reported outcomes, decentralized clinical trials, and real-world evidence platforms are improving patient monitoring, endpoint assessment, and clinical trial efficiency.

Clinical Development Trends

The multiple sclerosis clinical research landscape continues to diversify as developers pursue therapies capable of modifying disease progression while improving long-term neurological outcomes.

Key development trends include:

• Expansion of BTK inhibitor clinical programs.
• Development of remyelination and neuroregeneration therapies.
• Increasing research into neuroprotective treatment strategies.
• Greater use of biomarkers for patient stratification.
• Adoption of adaptive and decentralized clinical trial designs.
• Growing integration of artificial intelligence and digital technologies into clinical research.

Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations continue to accelerate innovation and strengthen the global MS clinical development landscape.

Regional Insights

North America remains the leading region for multiple sclerosis clinical research owing to advanced neuroscience research infrastructure, substantial pharmaceutical investment, high disease awareness, and supportive regulatory frameworks.

Europe represents another major research hub supported by strong academic collaborations, well-established MS treatment centers, and extensive participation in multinational clinical trials.

Asia-Pacific is expected to witness the fastest growth during the forecast period due to expanding biotechnology capabilities, improving healthcare infrastructure, increasing neurological research investment, and growing participation in global clinical trials across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa are gradually strengthening clinical research capabilities through healthcare modernization, improved diagnostic services, and increased international collaboration.

Competitive Landscape

The multiple sclerosis clinical trials landscape is highly competitive and includes multinational pharmaceutical companies, biotechnology firms, academic research institutions, contract research organizations, and neuroscience-focused developers.

Industry participants continue to invest in innovative immunotherapies, regenerative medicine, precision medicine, biomarker discovery, and artificial intelligence-enabled clinical development. Strategic collaborations, licensing agreements, mergers and acquisitions, and co-development partnerships remain central to strengthening clinical pipelines and accelerating product development.

Future Outlook

The future of multiple sclerosis clinical research is expected to be driven by advances in neuroimmunology, precision medicine, biomarker-guided treatment, regenerative medicine, and artificial intelligence. Emerging clinical programs are increasingly focused on progressive MS, remyelination, neuroprotection, and personalized treatment strategies that improve long-term functional outcomes.

Increasing collaboration among pharmaceutical companies, biotechnology firms, academic institutions, and healthcare organizations is expected to accelerate innovation while expanding global access to next-generation MS therapies.

Conclusion

The global Multiple Sclerosis Clinical Trials Landscape, Developments, and Analysis market is expected to experience sustained growth through 2035, supported by expanding investment in neuroscience research, continuous innovation in disease-modifying therapies, advances in clinical trial technologies, and growing adoption of precision medicine. Although challenges including disease heterogeneity, lengthy clinical development timelines, and patient recruitment remain, ongoing innovation in immunotherapy, regenerative medicine, biomarker research, and digital health technologies is expected to transform the future treatment landscape for multiple sclerosis.

Key Benefits of this Report

• Comprehensive analysis of the global multiple sclerosis clinical trial landscape and ongoing research activities.
• Detailed evaluation of pipeline trends, investigational therapies, and clinical development strategies.
• Competitive assessment of sponsors, research organizations, and strategic collaborations.
• Insights into regulatory developments, emerging technologies, and future clinical research opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, CROs, researchers, investors, healthcare providers, and policymakers.

What Businesses Use Our Reports For

Clinical pipeline monitoring, competitive intelligence, trial benchmarking, licensing evaluation, partnership identification, portfolio planning, investment analysis, regulatory strategy development, and commercialization planning.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive assessment of the global multiple sclerosis clinical trial landscape by clinical development phase, therapeutic approach, disease subtype, sponsor type, study design, and geography
• Analysis of ongoing, completed, recruiting, active, terminated, and planned clinical studies
• Evaluation of investigational therapies, clinical endpoints, patient recruitment trends, regulatory developments, and innovation strategies
• Competitive intelligence covering sponsor activities, strategic collaborations, licensing agreements, mergers and acquisitions, and pipeline benchmarking
• Future outlook on emerging immunotherapies, regenerative medicine, precision medicine, digital health technologies, and commercialization opportunities through 2035

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Global Multiple Sclerosis (MS) Clinical Development Snapshot
• 1.3 Key Pipeline Highlights
• 1.4 Clinical Development Trends by Phase
• 1.5 Innovation Landscape Overview
• 1.6 High-Potential Pipeline Assets (Verified Clinical Candidates Only)
• 1.7 Competitive Intelligence Summary
• 1.8 Probability-Adjusted Development Outlook
• 1.9 Commercial Opportunity Assessment
• 1.10 Strategic Takeaways

2. Global Multiple Sclerosis Clinical Pipeline Overview

• 2.1 Disease Landscape
  • 2.1.1 Disease Burden and Epidemiology
  • 2.1.2 Clinical Subtypes
    • 2.1.2.1 Relapsing-Remitting Multiple Sclerosis (RRMS)
    • 2.1.2.2 Secondary Progressive Multiple Sclerosis (SPMS)
    • 2.1.2.3 Primary Progressive Multiple Sclerosis (PPMS)
    • 2.1.2.4 Clinically Isolated Syndrome (CIS)
  • 2.1.3 Current Standard of Care
  • 2.1.4 Treatment Gaps
  • 2.1.5 Future Treatment Paradigm
• 2.2 Current Clinical Pipeline Snapshot
  • 2.2.1 Total Verified Pipeline Assets
  • 2.2.2 Active Clinical Trials
  • 2.2.3 Sponsors by Development Stage
  • 2.2.4 Pipeline Evolution (Historical Trends)
  • 2.2.5 Phase Distribution
  • 2.2.6 Mechanism Distribution
  • 2.2.7 Modality Distribution
  • 2.2.8 Route of Administration Analysis

3. Disease Biology & Unmet Need Analysis

• 3.1 Disease Pathophysiology
  • 3.1.1 Immune Dysregulation
  • 3.1.2 Neurodegeneration
  • 3.1.3 Demyelination
  • 3.1.4 Remyelination Failure
  • 3.1.5 Biomarker Landscape
• 3.2 Current Treatment Challenges
  • 3.2.1 Disease Progression
  • 3.2.2 Relapse Prevention
  • 3.2.3 Disability Progression
  • 3.2.4 Safety Limitations
  • 3.2.5 Long-Term Tolerability
  • 3.2.6 Treatment Adherence
  • 3.2.7 Progressive MS Management Challenges
• 3.3 Future Therapeutic Needs
  • 3.3.1 Neuroprotection
  • 3.3.2 Remyelination
  • 3.3.3 CNS Repair
  • 3.3.4 Precision Medicine
  • 3.3.5 Biomarker-Guided Therapy

4. Mechanism of Action & Therapeutic Modality Landscape

• 4.1 Mechanism of Action Landscape
  • 4.1.1 B-cell Targeted Therapies
  • 4.1.2 T-cell Modulation
  • 4.1.3 BTK Inhibitors
  • 4.1.4 Cytokine Modulators
  • 4.1.5 S1P Receptor Modulators
  • 4.1.6 Neuroprotective Agents
  • 4.1.7 Remyelination Therapies
  • 4.1.8 Immune Reconstitution Therapies
  • 4.1.9 Antigen-Specific Immune Tolerance
  • 4.1.10 Other Emerging Mechanisms
• 4.2 Mechanism-Based Competitive Clustering
  • 4.2.1 Established Mechanisms
  • 4.2.2 Novel Mechanisms
  • 4.2.3 First-in-Class Candidates
  • 4.2.4 Best-in-Class Candidates
  • 4.2.5 Combination Development Strategies
• 4.3 Therapeutic Modality Analysis
  • 4.3.1 Small Molecules
  • 4.3.2 Monoclonal Antibodies
  • 4.3.3 Cell Therapies
  • 4.3.4 Gene Therapies
  • 4.3.5 RNA-Based Therapeutics
  • 4.3.6 Peptide Therapies
  • 4.3.7 Vaccine-Based Therapeutics
  • 4.3.8 Other Emerging Modalities

5. Clinical Development Intelligence

• 5.1 Clinical Trial Landscape
  • 5.1.1 Trial Growth Trends
  • 5.1.2 Active vs Completed Studies
  • 5.1.3 Sponsor Distribution
  • 5.1.4 Academic vs Industry Trials
• 5.2 Clinical Trial Design Benchmarking
  • 5.2.1 Trial Design Evolution
  • 5.2.2 Randomization Patterns
  • 5.2.3 Blinding Strategies
  • 5.2.4 Comparator Selection
  • 5.2.5 Adaptive Trial Designs
  • 5.2.6 Basket and Platform Studies
• 5.3 Endpoint Benchmarking
  • 5.3.1 Annualized Relapse Rate
  • 5.3.2 Confirmed Disability Progression
  • 5.3.3 MRI Endpoints
  • 5.3.4 Brain Volume Loss
  • 5.3.5 Neurofilament Biomarkers
  • 5.3.6 Quality of Life Measures
  • 5.3.7 Safety Endpoints
• 5.4 Operational Intelligence
  • 5.4.1 Sample Size Benchmarking
  • 5.4.2 Study Duration Analysis
  • 5.4.3 Recruitment Timelines
  • 5.4.4 Enrollment Challenges
  • 5.4.5 Geographic Enrollment Trends
  • 5.4.6 Patient Retention
  • 5.4.7 Trial Completion Timelines
• 5.5 Historical Clinical Performance
  • 5.5.1 Success Rates by Phase
  • 5.5.2 Failure Analysis
  • 5.5.3 Program Discontinuation Trends
  • 5.5.4 Safety-Driven Failures
  • 5.5.5 Efficacy-Driven Failures
  • 5.5.6 Regulatory Setbacks

6. Pipeline Segmentation

• 6.1 Pipeline by Clinical Development Phase
  • 6.1.1 Preclinical Assets
  • 6.1.2 Phase I Assets
  • 6.1.3 Phase II Assets
  • 6.1.4 Phase III Assets
  • 6.1.5 Filed / Under Regulatory Review
• 6.2 Pipeline by Mechanism of Action
• 6.3 Pipeline by Therapeutic Modality
• 6.4 Pipeline by Disease Indication
  • 6.4.1 RRMS
  • 6.4.2 SPMS
  • 6.4.3 PPMS
  • 6.4.4 CIS
  • 6.4.5 Broad MS Population
• 6.5 Pipeline by Route of Administration
  • 6.5.1 Oral
  • 6.5.2 Intravenous
  • 6.5.3 Subcutaneous
  • 6.5.4 Intramuscular
  • 6.5.5 Intrathecal
  • 6.5.6 Other Routes
• 6.6 Asset-Level Clinical Profiles (Verified Candidates Only)

7. Probability of Success & Risk Analysis

• 7.1 Phase Transition Modeling
  • 7.1.1 Preclinical to Phase I
  • 7.1.2 Phase I to Phase II
  • 7.1.3 Phase II to Phase III
  • 7.1.4 Phase III to Approval
• 7.2 Historical Attrition Analysis
  • 7.2.1 Attrition by Mechanism
  • 7.2.2 Attrition by Modality
  • 7.2.3 Attrition by Sponsor Type
• 7.3 Risk Assessment
  • 7.3.1 Scientific Risk
  • 7.3.2 Clinical Risk
  • 7.3.3 Regulatory Risk
  • 7.3.4 Manufacturing Risk
  • 7.3.5 Commercial Risk
• 7.4 Risk-Adjusted Pipeline Valuation
• 7.5 Probability-Weighted Revenue Forecast

8. Launch Timeline & Commercial Potential

• 8.1 Expected Regulatory Submission Timeline
• 8.2 Expected Approval Timeline
• 8.3 Anticipated Product Launch Timeline
• 8.4 Launch Sequencing
• 8.5 Peak Sales Forecast
• 8.6 Market Penetration Potential
• 8.7 Competitive Entry Timeline
• 8.8 Commercial Opportunity by Mechanism
• 8.9 Commercial Opportunity by Modality

9. Competitive Pipeline Landscape

• 9.1 Company Pipeline Ranking
• 9.2 Company-Wise Clinical Portfolio Strength
• 9.3 Pipeline Concentration Analysis
• 9.4 Emerging Biotech Competitors
• 9.5 Large Pharmaceutical Company Positioning
• 9.6 Innovation Leadership Analysis
• 9.7 Leader vs Challenger Assessment
• 9.8 White Space Opportunity Analysis
• 9.9 Competitive Benchmarking Matrix

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Sponsor Presence
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Sponsor Presence
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Sponsor Presence
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Sponsor Presence
• 10.5 Middle East & Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Sponsor Presence

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Major Sponsors
  • 11.1.4 Research Centers
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Major Sponsors
• 11.3 Germany
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Major Sponsors
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Major Sponsors
• 11.5 France
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Major Sponsors
• 11.6 Italy
  • 11.6.1 Clinical Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Major Sponsors
• 11.7 Spain
  • 11.7.1 Clinical Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Major Sponsors
• 11.8 China
  • 11.8.1 Clinical Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Major Sponsors
• 11.9 Japan
  • 11.9.1 Clinical Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Major Sponsors
• 11.10 India
  • 11.10.1 Clinical Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Major Sponsors
• 11.11 South Korea
  • 11.11.1 Clinical Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Major Sponsors
• 11.12 Australia
  • 11.12.1 Clinical Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Major Sponsors
• 11.13 Brazil
  • 11.13.1 Clinical Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Major Sponsors
• 11.14 Mexico
  • 11.14.1 Clinical Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Major Sponsors
• 11.15 Saudi Arabia
  • 11.15.1 Clinical Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Major Sponsors
• 11.16 South Africa
  • 11.16.1 Clinical Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Major Sponsors

12. Deals & Investment Landscape

• 12.1 Licensing Agreements
• 12.2 Co-development Partnerships
• 12.3 Strategic Collaborations
• 12.4 Mergers & Acquisitions
• 12.5 Venture Capital Investments
• 12.6 Private Equity Investments
• 12.7 Public Financing Activities
• 12.8 Research Grants and Non-Dilutive Funding
• 12.9 Alliance Network Analysis
• 12.10 Deal Value Trends

13. Future Outlook & Strategic Insights

• 13.1 Emerging Scientific Trends
• 13.2 Future Mechanism Evolution
• 13.3 Next-Generation Therapeutic Modalities
• 13.4 Future Clinical Trial Design Trends
• 13.5 Biomarker-Driven Drug Development
• 13.6 Artificial Intelligence in MS Drug Development
• 13.7 Precision Medicine Outlook
• 13.8 Pipeline Evolution Forecast (5-10 Years)
• 13.9 Strategic Recommendations for Sponsors
• 13.10 Key Success Factors for Future Development

14. Methodology & Data Framework

• 14.1 Report Objectives
• 14.2 Inclusion and Exclusion Criteria
• 14.3 Pipeline Asset Validation Methodology
• 14.4 Clinical Trial Verification Framework
• 14.5 Phase Classification Methodology
• 14.6 Mechanism Classification Framework
• 14.7 Probability of Success Modeling Methodology
• 14.8 Commercial Forecasting Methodology
• 14.9 Competitive Intelligence Framework
• 14.10 Data Sources
  • 14.10.1 ClinicalTrials.gov
  • 14.10.2 EU Clinical Trials Information System (CTIS)
  • 14.10.3 Company Pipeline Disclosures
  • 14.10.4 Regulatory Agency Filings
  • 14.10.5 Scientific Publications and Conference Abstracts
• 14.11 Data Validation and Quality Assurance
• 14.12 Assumptions and Limitations
• 14.13 Glossary of Clinical Development Terms
• 14.14 Abbreviations and Acronyms